ImmunityBio, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+407.0% +$31M
$38M
Cost of Revenue
$382K
R&D
$35M
SG&A
$42M
D&A↓-6.6% -$273K
$4M
Operating Income↑+30.7% +$25M
$-56M
EBITDA↓-6.6% -$273K
$4M
Interest Expense↓-42.9% -$11M
$15M
Interest Income
—
Other Income/Expense↓-85.0% -$20M
$4M
Pretax Income↑+21.5% +$18M
$-67M
Tax Provision
$-35K
Net Income↑+21.6% +$18M
$-67M
Operating Margin↑+1140.8pts
-173.5%
Net Margin↑+1194.2pts
-209.8%
Effective Tax Rate↑+0.1pts
0.1%
Deferred Tax Liabilities
—
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-5.2pts
0.0%
ETR Foreign Differential (pp)
-0.2%
Operating Lease Cost↓-3.6% -$98K
$3M
Revenue YoY Variation↓-4926.1pts
407.0%
Income YoY Variation↑+30.8pts
30.7%
Revenue QoQ Variation↓-4.3pts
19.4%
Income QoQ Variation↑+2.8pts
22.0%